{"gene":"EHMT2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2011,"finding":"G9a and GLP exist predominantly as a G9a-GLP heteromeric complex that is the primary functional H3K9 methyltransferase in vivo, responsible for H3K9me1 and H3K9me2 in euchromatin.","method":"Biochemical characterization, genetic knockout studies in mammalian cells","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs, foundational finding supported by genetic KO and biochemical complex characterization","pmids":["21498567"],"is_preprint":false},{"year":2006,"finding":"EHMT2/G9a directly binds DNMT1 both in vivo and in vitro, colocalizes with DNMT1 at replication foci during DNA replication, and together with DNMT1 forms a ternary complex with PCNA on chromatin; this complex enhances both DNA and H3K9 methylation of in vitro assembled chromatin substrates.","method":"Co-immunoprecipitation, in vitro binding assay, colocalization studies, siRNA knockdown, in vitro chromatin methylation assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP, in vitro reconstitution, functional chromatin methylation assay, siRNA knockdown with defined mechanistic readout","pmids":["17085482"],"is_preprint":false},{"year":2008,"finding":"G9a/GLP complex suppresses transcription by independently inducing both H3K9 methylation and DNA methylation; catalytically inactive G9a/GLP mutants fail to rescue H3K9 methylation but still support DNA methylation-dependent gene silencing, demonstrating two distinct silencing mechanisms.","method":"ES cell catalytic mutant analysis, DNA methyltransferase inhibitor treatment, gene expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — catalytic mutant reconstitution in ES cells with multiple orthogonal readouts (H3K9me, DNA methylation, gene expression)","pmids":["18818694"],"is_preprint":false},{"year":2009,"finding":"G9a/KMT1C mediates mono- and dimethylation of histone H1.4 at lysine 26 (H1.4K26) in vitro and in vivo, providing a recognition surface for HP1 and L3MBTL1; G9a also promotes H1 deposition and is required for retention of H1 on chromatin.","method":"In vitro methyltransferase assay, in vivo ChIP, H1.4K26 methylation-specific antibodies, H1 chromatin retention assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro enzymatic assay plus in vivo validation, multiple orthogonal methods","pmids":["19144645"],"is_preprint":false},{"year":2010,"finding":"G9a/KMT1C and GLP1/KMT1D methylate histone H1.2 at lysine 187 (H1.2K187) in its C-terminus in vitro and in vivo; this methylation is variant-specific and distinct from H1.4K26 methylation in that it cannot recruit HP1 and is not reversed by JMJD2D/KDM4.","method":"In vitro methyltransferase assay, in vivo cell-based methylation analysis, HP1 binding assays, cell cycle analysis","journal":"Epigenetics & chromatin","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro and in vivo enzymatic assays with functional downstream reader analysis","pmids":["20334638"],"is_preprint":false},{"year":2008,"finding":"G9a binds the TNFα promoter in endotoxin-tolerant cells, dimethylates H3K9 creating a platform for HP1 binding, which recruits DNMT3a/b causing promoter CpG methylation and transcriptional silencing; G9a knockdown disrupts this silencing cascade.","method":"ChIP, RNA interference/siRNA knockdown, CpG methylation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and siRNA knockdown with defined mechanistic pathway, single lab","pmids":["18809684"],"is_preprint":false},{"year":2010,"finding":"LSH (encoded by Hells) is required for G9a/GLP complex recruitment to specific loci; in Hells-/- MEFs, G9a recruitment is compromised, impairing stable gene silencing and DNA methylation at specific promoters through a cooperative LSH–G9a/GLP mechanism.","method":"Genome-wide DNA methylation profiling, ChIP, Hells knockout MEFs","journal":"Genome research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide profiling plus ChIP in genetic KO model, single lab","pmids":["21149390"],"is_preprint":false},{"year":2012,"finding":"G9a functions within two distinct protein complexes: one containing the coactivator Mediator (for gene activation) and one containing the H3K4 demethylase Jarid1a/KDM5A (for gene repression); repressive function requires coordinate action of G9a-mediated H3K9me2/H3K27me2 and Jarid1a-mediated removal of H3K4me3.","method":"Co-immunoprecipitation, ChIP, genetic analysis in erythroid differentiation model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reciprocal Co-IP and ChIP, single lab, two orthogonal methods","pmids":["23112189"],"is_preprint":false},{"year":2012,"finding":"G9a mediates H3K9 dimethylation and DNA methylation at the Oct3/4 and Nanog promoters downstream of protein kinase A (PKA) signaling; G9a deletion abolishes PKA-driven acceleration of ESC differentiation, placing G9a as a PKA effector controlling differentiation timing.","method":"G9a knockout ESC/mouse model, PKA activation experiments, ChIP, bisulfite sequencing","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with phenotypic rescue, ChIP and DNA methylation analysis, signaling epistasis established","pmids":["22704517"],"is_preprint":false},{"year":2015,"finding":"EHMT2 binds specific genomic loci in embryonic cells (including CpG-rich promoters of germline-specific genes), is marked by H3K9me2, and is required for DNA methylation at these loci; EHMT2-mediated DNA methylation is instrumental for gene silencing at these loci during embryogenesis.","method":"Ehmt2 knockout mouse model, genome-wide DNA methylation analysis, ChIP","journal":"Genome research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with genome-wide methylation profiling and ChIP, multiple orthogonal methods","pmids":["26576615"],"is_preprint":false},{"year":2016,"finding":"G9a exists as two isoforms distinguished by alternative splicing of exon 10 (E10); E10 inclusion increases G9a nuclear localization and overall H3K9me2 levels without affecting catalytic activity, and the E10+ isoform is necessary for neuronal differentiation; G9a promotes E10 inclusion creating a positive feedback loop.","method":"Alternative splicing analysis, nuclear/cytoplasmic fractionation, H3K9me2 measurement, neuronal differentiation assays, G9a knockdown","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — subcellular fractionation tied to functional consequence, differentiation assays, single lab","pmids":["26997278"],"is_preprint":false},{"year":2016,"finding":"G9a blocks myogenic cell cycle exit via methylation-dependent transcriptional repression of p21(Cip/Waf1) and Rb1 (MyoD target genes), and activates E2F1-target genes in a methyltransferase activity-independent manner by associating with the E2F1/PCAF complex to enhance PCAF occupancy and histone acetylation at E2F1-target promoters.","method":"ChIP, Co-immunoprecipitation, G9a knockdown, transcriptome analysis, cell cycle assays","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP with functional KD, single lab, two orthogonal mechanisms defined","pmids":["27229136"],"is_preprint":false},{"year":2017,"finding":"In response to DNA double-strand breaks, G9a is phosphorylated at serine 211 by casein kinase 2 (CK2), recruited to chromatin, and directly interacts with the replication protein A (RPA) complex to promote RPA and Rad51 loading at DSBs, facilitating homologous recombination repair.","method":"Phosphorylation mapping, Co-immunoprecipitation, RPA foci formation assays, HR repair assays, CK2 inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — phosphorylation site identification, reciprocal Co-IP with RPA, functional HR assay, multiple orthogonal methods","pmids":["28698370"],"is_preprint":false},{"year":2017,"finding":"ATM phosphorylates G9a on serine 569, which is required for its recruitment to DNA breaks; G9a catalytic activity is required for early recruitment of DNA repair factors 53BP1 and BRCA1 to DNA breaks.","method":"Phosphorylation site mutation, DNA damage foci analysis, G9a catalytic inhibition, ionizing radiation sensitivity assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — phosphorylation mapping and foci assays, single lab","pmids":["29192276"],"is_preprint":false},{"year":2017,"finding":"G9a protein stability is increased under hypoxia via reduced proline hydroxylation leading to inefficient proteasomal degradation, resulting in increased H3K9me2 at target promoters and repression of specific genes.","method":"Protein stability assays, proline hydroxylation analysis, proteasome inhibition, ChIP, in vitro and in vivo tumor growth assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — mechanistic dissection of post-translational stability, ChIP, single lab","pmids":["28630300"],"is_preprint":false},{"year":2017,"finding":"G9a forms a complex with MEF2C transcription factor in cardiomyocytes and represses key cardiac function genes via H3K9me2; G9a also interacts with EZH2 (PRC2 catalytic subunit) and is required for maintenance of heterochromatin and silencing of developmental genes in the adult heart.","method":"Conditional cardiac-specific G9a KO mouse, ChIP-seq, RNA-seq, Co-immunoprecipitation","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with ChIP-seq and RNA-seq plus Co-IP, multiple orthogonal methods","pmids":["28778944"],"is_preprint":false},{"year":2019,"finding":"G9a methylates FOXO1 at K273 in vitro and in vivo; this methylation increases FOXO1 interaction with E3 ligase SKP2, decreasing FOXO1 protein stability and promoting colon cancer cell proliferation; insulin increases G9a expression, resulting in insulin-mediated FOXO1 degradation via K273 methylation.","method":"In vitro methylation assay, Co-immunoprecipitation, protein stability assay, proliferation and apoptosis assays","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzymatic assay, Co-IP for reader interaction, functional cell assays, single lab","pmids":["30535125"],"is_preprint":false},{"year":2015,"finding":"G9a (EHMT2) promotes H3K27 methylation by upregulating PCL3 (increasing PRC2 promoter recruitment) and downregulating H3K27 demethylase KDM7A; G9a physically interacts with EZH2 to repress E-cadherin expression and induce EMT in pancreatic cancer cells.","method":"Co-immunoprecipitation, ChIP, siRNA knockdown, overexpression experiments","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP with functional knockdown, single lab","pmids":["26688070"],"is_preprint":false},{"year":2016,"finding":"G9a interacts with human G9a (hG9a) but unlike mouse G9a, human G9a potently stimulates p53 transcriptional activity independent of its methyltransferase activity; hG9a interacts with histone acetyltransferase p300/CBP resulting in increased histone acetylation at the Puma promoter.","method":"Co-immunoprecipitation, ChIP, luciferase reporter, shRNA knockdown, apoptosis and colony assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP, single lab, human vs. mouse orthologue distinction made","pmids":["27452519"],"is_preprint":false},{"year":2019,"finding":"SUMOylation of G9a at K79, K152, K256, and K799 is required for its function as an activator of myoblast proliferation; SUMOylation acts as a signal for PCAF recruitment at E2F1-target genes, increasing H3K9 acetylation and S-phase progression, but does not affect G9a-mediated repression of MyoD activity.","method":"SUMOylation site mutagenesis, complementation assays in G9a conditional KO primary myoblasts, ChIP, cell cycle analysis","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — site-specific mutagenesis, genetic complementation in primary KO cells, ChIP, multiple orthogonal methods","pmids":["30867409"],"is_preprint":false},{"year":2019,"finding":"EHMT2/G9a and EZH2 physically interact with each other at the CXCL10 promoter in IPF fibroblasts; EZH2 knockdown reduces G9a and H3K9me3, and G9a knockdown reduces EZH2 and H3K27me3, demonstrating a functionally interdependent interplay mediating epigenetic repression of CXCL10.","method":"ChIP, Re-ChIP, proximity ligation assay, siRNA knockdown","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — proximity ligation assay and ChIP, single lab, two orthogonal methods","pmids":["29053336"],"is_preprint":false},{"year":2019,"finding":"G9a promotes H3K9me2-dependent silencing of pro-inflammatory cytokines (including TNF) in recurrent mammary tumors; G9a-mediated silencing suppresses necroptosis and tumor recurrence.","method":"G9a genetic ablation, ChIP, gene expression analysis, cell death assays in recurrent tumor models","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic ablation with ChIP and functional cell death readout, single lab","pmids":["33147463"],"is_preprint":false},{"year":2020,"finding":"G9a regulates chromatin accessibility, epigenetic modifications, and transcriptional silencing in both catalytic-dependent and catalytic-independent manners; loss of G9a leads to altered CTCF and cohesin binding and differential chromatin looping, especially at retrotransposons, while topologically associated domains are largely unaffected.","method":"G9a depletion and catalytic mutant ESC lines, ATAC-seq, ChIP-seq, RNA-seq, Hi-C","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genome-wide orthogonal approaches in catalytic mutant plus depletion models","pmids":["33113380"],"is_preprint":false},{"year":2020,"finding":"G9a gain-of-function mutations and copy number gains in melanoma suppress WNT antagonist DKK1 expression through H3K9me2-mediated promoter methylation, activating WNT/β-catenin signaling and driving tumor growth and immune exclusion.","method":"Oncogenic G9a mutation identification, ChIP, genetic/pharmacologic G9a suppression in vitro and in vivo tumor models","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and genetic/pharmacologic inhibition with in vivo models, single study","pmids":["32269030"],"is_preprint":false},{"year":2021,"finding":"SPOP E3 ligase binds GLP and promotes its polyubiquitination and proteasomal degradation; SPOP mutation stabilizes GLP and its partner G9a, leading to aberrant global DNA hypermethylation and silencing of tumor suppressor genes in prostate cancer.","method":"Co-immunoprecipitation, ubiquitination assay, SPOP mutant cell lines, genome-wide DNA methylome analysis, xenograft models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP, ubiquitination assay, genome-wide methylome, in vivo models, multiple orthogonal methods","pmids":["34588438"],"is_preprint":false},{"year":2021,"finding":"Heterodimerization of G9a and GLP (heterodimer) significantly enhances both H3K9me2 reading (recognition) and writing (catalytic turnover) activities compared to homodimers; the heterodimer shows ~10-fold increased turnover on nucleosomal substrates; cross-linking mass spectrometry reveals distinct domain contacts between heterodimer vs. homodimers suggesting relieved autoinhibition.","method":"Recombinant homodimer/heterodimer production, in vitro methyltransferase assay, nucleosomal substrate assay, cross-linking mass spectrometry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with defined dimers, nucleosomal substrates, cross-linking MS structural analysis","pmids":["34619147"],"is_preprint":false},{"year":2016,"finding":"G9a/GLP complex maintains imprinted DNA methylation at imprinting control regions (ICRs) in ESCs through a catalytic activity-independent mechanism; the complex protects imprinted DNA methylation by recruiting de novo DNA methyltransferases that antagonize TET dioxygenase-dependent erosion, not through H3K9me2.","method":"G9a/GLP knockout and catalytic mutant ESCs, allele-specific DNA methylation analysis, TET dioxygenase assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO plus catalytic mutant with allele-specific methylation, multiple orthogonal approaches","pmids":["27052169"],"is_preprint":false},{"year":2019,"finding":"EHMT2 and SETDB1 in oocytes provide H3K9me2 and H3K9me3, respectively, to the maternal pronucleus; genetic deletion of the EHMT2 catalytic domain in oocytes reduces H3K9me2 and increases TET3-mediated 5mC oxidation (5hmC, 5fC, 5caC) in the maternal pronucleus, demonstrating that oocyte-derived EHMT2 H3K9 methylation protects maternal DNA from oxidative demethylation.","method":"Oocyte-specific conditional KO of EHMT2 catalytic domain, immunofluorescence for 5mC/5hmC/5fC/5caC in zygotes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic catalytic domain deletion in oocytes with functional 5mC oxidation readout, direct epistasis","pmids":["31088968"],"is_preprint":false},{"year":2019,"finding":"G9a (EHMT2) is required for TGFβ- and matrix stiffness-induced fibroblast activation; G9a and CBX5 (HP1α) form a repressor complex that deposits H3K9me marks to silence PPARGC1A (PGC1α) expression, sustaining fibroblast activation in pulmonary fibrosis.","method":"G9a inhibition and knockdown, ChIP, TGFβ and mechanical stiffness stimulation, bleomycin lung injury model","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and genetic/pharmacologic inhibition in primary cells and in vivo model, single lab","pmids":["31095524"],"is_preprint":false},{"year":2017,"finding":"G9a activates the Notch pathway in placental endothelial progenitors to balance endothelial and trophoblast proliferation; G9a-deficient endothelial progenitors show downregulated Notch effectors including Rbpj, and Notch pathway activation rescues placental vascular defects.","method":"Conditional G9a KO in endothelial progenitors, in vivo vascular analysis, Notch activation rescue experiments","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional genetic KO with pathway rescue, in vivo model, single lab","pmids":["28455378"],"is_preprint":false},{"year":2022,"finding":"ZFP462 (murine homologue of ZNF462) recruits the G9A/GLP complex to transposable element-containing enhancers harbouring pluripotency and meso-endoderm transcription factor binding sites, seeding heterochromatin to restrict transcription factor binding and silence meso-endodermal genes during neural lineage specification.","method":"ZFP462 screen and KO in ESCs, ChIP-seq, ATAC-seq, Co-IP showing ZFP462-G9A/GLP interaction","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP plus genome-wide ChIP-seq and ATAC-seq in genetic KO model, multiple orthogonal methods","pmids":["36604593"],"is_preprint":false},{"year":2022,"finding":"PALI1 interacts with G9A and bridges formation of a G9A-PALI1-PRC2 super-complex that occupies a subset of G9A-target genes to mediate dual H3K9/K27 methylation and gene repression, promoting prostate cancer cell proliferation and invasion.","method":"Co-immunoprecipitation, ChIP-seq, genetic knockdown, in vitro and xenograft tumor models","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP for complex formation, ChIP-seq for genomic occupancy, functional in vivo models","pmids":["36476474"],"is_preprint":false},{"year":2019,"finding":"Cyclin D1 directly associates with G9a and is required for G9a recruitment to target gene chromatin and for G9a-induced H3K9me2; cyclin D1 is also required for nuclear lamina-lamina-associated domain (LAD) interactions dependent on G9a-mediated H3K9me2.","method":"Co-immunoprecipitation, ChIP, cyclin D1 genetic requirement assays, LAD interaction analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP, single lab, two orthogonal methods","pmids":["30718920"],"is_preprint":false},{"year":2001,"finding":"NG36 and G9a are expressed as a single ~3.9 kb transcript in human and mouse cells; the full-length NG36/G9a protein is concentrated exclusively in the nucleus, whereas the G9a region alone (aa 210-1210) localizes to both cytoplasm and nucleus and is marginalized at the nuclear periphery—demonstrating that the NG36 domain controls nuclear localization of the protein.","method":"Expression cloning, T7-epitope tagged subcellular localization in transiently transfected mammalian cells, RT-PCR for splice variants","journal":"Mammalian genome","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct subcellular localization experiment with domain deletion, but single lab and no functional readout beyond localization","pmids":["11707778"],"is_preprint":false},{"year":2021,"finding":"G9a directly binds and methylates GMFB (glia maturation factor β) at lysine 20 and K25 in vitro; methylation at K25 suppresses GMFB neuroprotective activity; G9a pharmacological inhibition removes K25 methylation, increasing GMFB activity and promoting neuroprotective effects in Alzheimer's disease models.","method":"In vitro methylation assay identifying K20 and K25, ChIP-seq after G9a inhibition, pharmacological inhibition in mouse model and C. elegans","journal":"Aging and disease","confidence":"Medium","confidence_rationale":"Tier 1–3 / Moderate — in vitro methylation assay identifying sites, in vivo ChIP-seq, but limited mutagenesis validation in vivo","pmids":["37307824"],"is_preprint":false},{"year":2019,"finding":"G9a promotes mTOR expression through H3K9 monomethylation at the mTOR promoter (not dimethylation); G9a knockdown decreases H3K9 monomethylation at the mTOR promoter and reduces mTOR expression, thereby suppressing gastric cancer cell proliferation and inducing autophagy.","method":"ChIP analysis of H3K9me1/me2 at mTOR promoter, G9a siRNA and inhibitor treatment, mTOR rescue experiments","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP with functional rescue, single lab","pmids":["31647887"],"is_preprint":false},{"year":2021,"finding":"EHMT2 controls H3K9me2 at ERVK (endogenous retrovirus K) promoters on the maternal allele of noncanonical imprinted genes in the ectoplacental cone; in Ehmt2 embryos, loss of H3K9me2 and DNA methylation at ERVK promoters leads to biallelic derepression of noncanonical imprinted genes.","method":"Allele-specific RNA-seq in Ehmt2 KO embryos, reciprocal mouse crosses, ERVK promoter methylation analysis","journal":"Epigenomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — allele-specific RNA-seq in genetic KO with DNA methylation analysis, single lab","pmids":["34519223"],"is_preprint":false},{"year":2023,"finding":"G9a binds the Fbxw7 promoter and represses its transcription via H3K9me2, thereby activating the Notch pathway and promoting stemness in glioma stem cells and an immunosuppressive tumor microenvironment.","method":"ChIP, dual-luciferase reporter assay, G9a inhibition/knockdown, flow cytometry for immune cells in orthotopic model","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP and luciferase reporter validation of direct promoter interaction, single lab","pmids":["36971192"],"is_preprint":false},{"year":2022,"finding":"CHD4 represses galectin-7 expression by recruiting EHMT2 to form a co-transcriptional silencing complex; EHMT2 inhibition disrupts this complex, inducing galectin-7 expression and converting immunosuppressive MSS colorectal cancer to an immunomodulatory state.","method":"CRISPR screen, co-immunoprecipitation, ChIP, functional immune co-culture assays","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and ChIP with CRISPR screen validation, single lab","pmids":["38065340"],"is_preprint":false},{"year":2021,"finding":"EHMT2 directly mediates H3K9me2 methylation of the APC promoter to epigenetically silence APC expression, activating Wnt-β-catenin signaling in hepatocellular carcinoma.","method":"EHMT2 CRISPR KO, ChIP for H3K9me2 at APC promoter, rescue experiments with APC overexpression, xenograft assays","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP with genetic rescue and functional KO, single lab","pmids":["34344448"],"is_preprint":false},{"year":2023,"finding":"c-Myc interacts with G9a in HCC, cooperating to regulate c-Myc-dependent gene repression; G9a stabilizes c-Myc protein to promote cancer growth and invasion.","method":"Co-immunoprecipitation, c-Myc/G9a co-expression knockdown and overexpression, xenograft and patient-derived xenograft models","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP with functional in vivo models, single lab","pmids":["36896891"],"is_preprint":false},{"year":2022,"finding":"EHMT2 increases methylation of the SFRP1 promoter region, reducing SFRP1 expression and activating the WNT/β-catenin pathway to drive neuroendocrine transformation and TKI resistance in lung adenocarcinoma.","method":"ChIP for H3K9me2/DNA methylation at SFRP1 promoter, EHMT2 inhibitor rescue, CDX mouse models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — ChIP with in vivo rescue model, single lab","pmids":["38814866"],"is_preprint":false},{"year":2022,"finding":"Discovery of first-in-class covalent G9a/GLP inhibitors targeting a cysteine at the substrate binding site; X-ray crystallography confirmed covalent binding mode; compound 8 (MS8511) showed improved potency over noncovalent inhibitor UNC0642 and potential kinetic preference for G9a over GLP.","method":"Covalent inhibitor synthesis, enzymatic assay, mass spectrometry-based covalent modification confirmation, X-ray crystallography, cellular H3K9me2 assay","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — X-ray crystal structure with MS covalent modification confirmation and enzymatic assay, single lab","pmids":["35763668"],"is_preprint":false},{"year":2017,"finding":"G9a inhibition in the nucleus accumbens (NAc) blocks stress-regulated changes in ethanol drinking including kappa-opioid receptor-stimulated potentiation of alcohol drinking, demonstrating that NAc G9a is specifically required for stress-regulated (not baseline) alcohol drinking behavior.","method":"Viral-mediated G9a knockdown in NAc, chronic intermittent ethanol (CIE) mouse model, pharmacological G9a inhibition","journal":"Addiction biology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — region-specific viral KD with behavioral readout, single lab","pmids":["34013595"],"is_preprint":false},{"year":2014,"finding":"G9a-mediated H3K9me2 in naive T cells restricts Th17 and Treg differentiation by limiting chromatin accessibility and TGF-β1 responsiveness; H3K9me2 is lost upon T cell activation, and G9a loss increases chromatin accessibility and TGF-β1 sensitivity to promote Th17/Treg differentiation.","method":"T cell-specific G9a KO mice, T cell transfer colitis model, in vitro differentiation assays, ChIP for H3K9me2, ATAC-seq/chromatin accessibility","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic T cell-specific KO with in vivo model and ChIP, multiple orthogonal methods","pmids":["24667637"],"is_preprint":false}],"current_model":"EHMT2/G9a is a SET domain histone lysine methyltransferase that functions primarily as a heterodimer with GLP to catalyze H3K9me1 and H3K9me2 in euchromatin (heterodimerization enhancing both reading and writing ~10-fold over homodimers); it directly binds DNMT1 and PCNA at replication forks to coordinate H3K9 and DNA methylation, methylates non-histone substrates including H1.4K26, H1.2K187, FOXO1-K273, and GMFB-K25 to regulate their stability or activity, is recruited to DNA double-strand breaks via CK2-mediated phosphorylation at Ser211 to promote RPA/Rad51 loading and homologous recombination, and is regulated by SUMOylation (activating its co-activator function at E2F1 targets), prolyl hydroxylation (controlling proteasomal stability under hypoxia), and SPOP-mediated ubiquitination of its partner GLP; it additionally functions as a scaffold (independently of catalytic activity) in complexes with Mediator, PCAF, MEF2C, ZFP462, CHD4, and PALI1-PRC2 to control transcriptional programs in development, immune differentiation, DNA repair, and cancer."},"narrative":{"mechanistic_narrative":"EHMT2 (G9a) is a SET-domain histone lysine methyltransferase that operates predominantly as a G9a-GLP heterodimer, the principal enzyme generating H3K9me1 and H3K9me2 in euchromatin [PMID:21498567]; heterodimerization relieves autoinhibition and enhances both H3K9me2 recognition and catalytic turnover roughly 10-fold over homodimers on nucleosomes [PMID:34619147]. It couples H3K9 methylation to DNA methylation by binding DNMT1 and forming a ternary complex with PCNA at replication foci, and by establishing H3K9me2/HP1 platforms that recruit de novo DNA methyltransferases to silence target promoters [PMID:17085482, PMID:18809684]; catalytic and DNA-methylation-dependent silencing are mechanistically separable, and several G9a functions—including protection of imprinted DNA methylation and transcriptional co-activation—are independent of its catalytic activity [PMID:18818694, PMID:27052169]. Through these activities G9a controls developmental and lineage programs, silencing germline, meso-endodermal, and cardiac genes and protecting maternal and imprinted DNA from TET-mediated demethylation [PMID:26576615, PMID:28778944, PMID:31088968, PMID:36604593], and restraining Th17/Treg differentiation in naive T cells [PMID:24667637]. Beyond histones, G9a methylates non-histone substrates including histone H1 variants (H1.4K26, H1.2K187), FOXO1-K273 to drive its SKP2-dependent degradation, and GMFB-K25 [PMID:19144645, PMID:20334638, PMID:30535125, PMID:37307824]. G9a is regulated by signaling and post-translational modification: CK2- and ATM-dependent phosphorylation recruit it to DNA double-strand breaks to promote RPA/Rad51 loading and homologous recombination [PMID:28698370, PMID:29192276], SUMOylation activates its PCAF-dependent co-activator function at E2F1 targets [PMID:30867409], prolyl hydroxylation controls its stability under hypoxia [PMID:28630300], and SPOP-mediated ubiquitination of its partner GLP governs heterodimer abundance [PMID:34588438]. It further acts as a scaffold within complexes containing Mediator, EZH2/PRC2 (via PALI1), CHD4, MEF2C, and ZFP462 to coordinate H3K9 and H3K27 methylation and shape transcriptional programs in development and cancer [PMID:23112189, PMID:28778944, PMID:36604593, PMID:36476474, PMID:38065340]. In tumors G9a drives oncogenic programs by silencing WNT antagonists (DKK1, APC, SFRP1) and tumor suppressors and by stabilizing c-Myc [PMID:32269030, PMID:34344448, PMID:36896891, PMID:38814866].","teleology":[{"year":2001,"claim":"Established that the full-length protein is exclusively nuclear and identified a domain controlling its nuclear localization, defining where G9a acts.","evidence":"Epitope-tagged subcellular localization with domain deletion in transfected mammalian cells","pmids":["11707778"],"confidence":"Medium","gaps":["No functional readout beyond localization","Single lab","NLS not mapped at residue level"]},{"year":2006,"claim":"Showed G9a physically links H3K9 methylation to the DNA replication and methylation machinery, answering how the two epigenetic marks are coordinated.","evidence":"Reciprocal Co-IP, in vitro binding, replication foci colocalization, in vitro chromatin methylation assay","pmids":["17085482"],"confidence":"High","gaps":["Stoichiometry and order of complex assembly at forks unresolved","Direct vs DNMT1-bridged PCNA contact not fully separated"]},{"year":2008,"claim":"Demonstrated G9a silences genes through two separable routes—H3K9 methylation and DNA methylation—revealing a catalytic-independent silencing arm.","evidence":"Catalytic-inactive mutant reconstitution in ES cells with DNMT inhibitor and expression readouts; ChIP/siMethylation in tolerant cells","pmids":["18818694","18809684"],"confidence":"High","gaps":["Catalytic-independent DNA methylation recruitment mechanism not defined","TNFa promoter cascade from single lab"]},{"year":2010,"claim":"Identified histone H1 variants as direct G9a substrates, extending its writing activity beyond core histones and defining variant-specific reader outcomes.","evidence":"In vitro and in vivo methyltransferase assays with site-specific antibodies and HP1/L3MBTL1 binding analysis","pmids":["19144645","20334638"],"confidence":"High","gaps":["In vivo functional consequences of H1.2K187 methylation limited","Cooperativity with histone substrate methylation unclear"]},{"year":2012,"claim":"Placed G9a within distinct activating (Mediator) and repressive (Jarid1a) complexes and as a PKA effector controlling differentiation timing, showing context-dependent dual function.","evidence":"Co-IP, ChIP, genetic erythroid model; G9a KO ESC with PKA activation and epistasis","pmids":["23112189","22704517"],"confidence":"High","gaps":["Switch between activating and repressive complexes not mechanistically defined","Mediator-G9a interface unmapped"]},{"year":2015,"claim":"Confirmed genome-wide that G9a directs DNA methylation and silencing at germline-gene promoters in embryos and interacts with EZH2 to drive EMT, linking H3K9 and H3K27 pathways.","evidence":"Ehmt2 KO mouse with genome-wide methylation and ChIP; Co-IP/ChIP in pancreatic cancer cells","pmids":["26576615","26688070"],"confidence":"Medium","gaps":["Direct vs indirect EZH2 cooperation not separated","Locus-selection determinants unknown"]},{"year":2016,"claim":"Revealed catalytic-independent and isoform-dependent layers: protection of imprinted DNA methylation without H3K9me2, splice-driven nuclear localization, and human-specific p53 co-activation.","evidence":"G9a/GLP KO and catalytic-mutant ESCs with allele-specific methylation; alternative splicing/fractionation; Co-IP and reporter assays for p53/p300","pmids":["27052169","26997278","27452519"],"confidence":"High","gaps":["Mechanism by which the complex recruits de novo DNMTs catalytically-independently unresolved","Species divergence in p53 regulation unexplained"]},{"year":2017,"claim":"Established G9a as a phosphorylation-regulated DNA repair factor and defined post-translational and complex-based controls over its stability and tissue function.","evidence":"CK2/ATM phospho-site mapping, RPA/Rad51 and 53BP1/BRCA1 foci, HR assays; prolyl hydroxylation stability assays; cardiac conditional KO with ChIP-seq/RNA-seq and MEF2C/EZH2 Co-IP; Notch rescue in placenta","pmids":["28698370","29192276","28630300","28778944","28455378"],"confidence":"High","gaps":["Whether DSB recruitment requires catalytic activity vs scaffolding partly conflicting","Substrates methylated at break sites not fully defined"]},{"year":2019,"claim":"Expanded the non-histone substrate and regulatory repertoire (FOXO1-K273 degradation, SUMO-driven PCAF co-activation) and detailed fibrosis and chromatin-loop functions.","evidence":"In vitro methylation and SKP2 Co-IP; SUMO site mutagenesis with myoblast complementation and ChIP; cyclin D1 Co-IP/ChIP/LAD analysis; G9a-CBX5 ChIP in fibrosis models; EZH2 interplay by PLA/Re-ChIP","pmids":["30535125","30867409","30718920","31095524","29053336","31088968","31647887"],"confidence":"High","gaps":["Generality of non-histone methylation across tissues untested","How SUMO toggles activator vs repressor states unresolved"]},{"year":2020,"claim":"Defined G9a's genome-architectural role and its oncogenic gain-of-function, showing it shapes chromatin accessibility/looping and drives WNT-dependent tumor growth and immune exclusion.","evidence":"ATAC-seq/ChIP-seq/Hi-C in depletion and catalytic-mutant ESCs; oncogenic mutation analysis with ChIP and in vivo melanoma models; recurrent tumor genetic ablation with necroptosis readouts","pmids":["33113380","32269030","33147463"],"confidence":"High","gaps":["Mechanism connecting H3K9me2 loss to altered CTCF/cohesin binding unclear","Catalytic vs scaffold contribution to looping not separated"]},{"year":2021,"claim":"Resolved the biochemical basis of heterodimer superiority, defined SPOP-GLP-G9a stability control, and broadened oncogenic and substrate repertoire including GMFB methylation.","evidence":"Recombinant dimer reconstitution with nucleosomes and XL-MS; SPOP Co-IP/ubiquitination/methylome/xenografts; in vitro GMFB methylation with in vivo neuroprotection models; APC/ERVK ChIP in KO models","pmids":["34619147","34588438","37307824","34344448","34519223"],"confidence":"High","gaps":["Structural model of full heterodimer absent","In vivo mutagenesis validation for GMFB-K25 limited"]},{"year":2022,"claim":"Established scaffolding super-complexes (PALI1-PRC2, ZFP462, CHD4) coordinating dual H3K9/K27 methylation and immune evasion, and delivered first covalent G9a/GLP inhibitors with a crystallographic binding mode.","evidence":"Co-IP and ChIP-seq for PALI1 and ZFP462 complexes in cancer and ESC KO models; CRISPR screen and Co-IP for CHD4; covalent inhibitor synthesis with X-ray structure and cellular H3K9me2 assays","pmids":["36476474","36604593","38065340","35763668"],"confidence":"High","gaps":["Determinants selecting dual-methylation target subsets unknown","G9a vs GLP selectivity of covalent inhibitors only partial"]},{"year":2023,"claim":"Extended oncogenic mechanisms to Notch activation via Fbxw7 silencing and c-Myc stabilization, reinforcing G9a as a transcriptional and protein-stability hub in cancer.","evidence":"ChIP/luciferase in glioma stem cells with immune profiling; c-Myc/G9a Co-IP and PDX models","pmids":["36971192","36896891"],"confidence":"Medium","gaps":["Whether c-Myc stabilization is methylation-dependent unresolved","Single-lab findings"]},{"year":null,"claim":"How G9a is targeted to specific genomic loci across its many partner-defined complexes, and what distinguishes its catalytic from scaffolding contributions at each target, remains the central unresolved question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of locus selection across Mediator/PRC2/CHD4/ZFP462 contexts","Catalytic vs scaffold contribution not systematically dissected genome-wide","Structural basis of heterodimer at nucleosomes incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,4,16,25,34]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[16,34]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[3,25]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[7,11,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[33]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[1,9]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,2,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,9,15]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[12,13]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,27,29,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,24,31,39]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[44,21]}],"complexes":["G9a-GLP heterodimer","G9a-PALI1-PRC2 super-complex","G9a-DNMT1-PCNA ternary complex","G9a-Mediator complex"],"partners":["GLP","DNMT1","PCNA","EZH2","RPA","MEF2C","CHD4","ZFP462"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96KQ7","full_name":"Histone-lysine N-methyltransferase EHMT2","aliases":["Euchromatic histone-lysine N-methyltransferase 2","HLA-B-associated transcript 8","Histone H3-K9 methyltransferase 3","H3-K9-HMTase 3","Lysine N-methyltransferase 1C","Protein G9a"],"length_aa":1210,"mass_kda":132.4,"function":"Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones (PubMed:11316813, PubMed:20084102). Also mediates monomethylation of 'Lys-56' of histone H3 (H3K56me1) in G1 phase, leading to promote interaction between histone H3 and PCNA and regulating DNA replication (PubMed:22387026). Also weakly methylates 'Lys-27' of histone H3 (H3K27me) (PubMed:11316813). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. Also able to mono- and dimethylate histone H1-4 at 'Lys-26' (H1.4K26me1 and H1.4K26me2, respectively) (PubMed:19144645). In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53 (PubMed:20118233). Also methylates CDYL, WIZ, ACIN1, DNMT1, HDAC1, ERCC6, KLF12 and itself (PubMed:18438403)","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q96KQ7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EHMT2","classification":"Not Classified","n_dependent_lines":139,"n_total_lines":1208,"dependency_fraction":0.11506622516556292},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CBX1","stoichiometry":0.2},{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"HDAC2","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/EHMT2","total_profiled":1310},"omim":[{"mim_id":"620008","title":"H2A.Z VARIANT HISTONE 2; H2AZ2","url":"https://www.omim.org/entry/620008"},{"mim_id":"619715","title":"WIZ ZINC FINGER PROTEIN; WIZ","url":"https://www.omim.org/entry/619715"},{"mim_id":"619640","title":"LYSINE DEMETHYLASE 7A; KDM7A","url":"https://www.omim.org/entry/619640"},{"mim_id":"617734","title":"ZINC FINGER PROTEIN 518B; ZNF518B","url":"https://www.omim.org/entry/617734"},{"mim_id":"617733","title":"ZINC FINGER PROTEIN 518A; ZNF518A","url":"https://www.omim.org/entry/617733"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/EHMT2"},"hgnc":{"alias_symbol":["G9A","Em:AF134726.3","NG36/G9a","KMT1C"],"prev_symbol":["C6orf30","BAT8"]},"alphafold":{"accession":"Q96KQ7","domains":[{"cath_id":"-","chopping":"430-547","consensus_level":"high","plddt":86.0356,"start":430,"end":547},{"cath_id":"1.25.40.20","chopping":"612-733","consensus_level":"medium","plddt":88.6072,"start":612,"end":733},{"cath_id":"1.25.40.20","chopping":"744-810","consensus_level":"medium","plddt":95.4722,"start":744,"end":810},{"cath_id":"1.25.40.20","chopping":"812-916","consensus_level":"medium","plddt":91.1944,"start":812,"end":916},{"cath_id":"2.170.270.10","chopping":"919-1153","consensus_level":"high","plddt":95.3691,"start":919,"end":1153},{"cath_id":"-","chopping":"1159-1184","consensus_level":"medium","plddt":92.3462,"start":1159,"end":1184}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KQ7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KQ7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KQ7-F1-predicted_aligned_error_v6.png","plddt_mean":68.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EHMT2","jax_strain_url":"https://www.jax.org/strain/search?query=EHMT2"},"sequence":{"accession":"Q96KQ7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96KQ7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96KQ7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KQ7"}},"corpus_meta":[{"pmid":"21498567","id":"PMC_21498567","title":"H3K9 methyltransferase G9a and the related molecule GLP.","date":"2011","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/21498567","citation_count":460,"is_preprint":false},{"pmid":"17085482","id":"PMC_17085482","title":"Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication.","date":"2006","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/17085482","citation_count":419,"is_preprint":false},{"pmid":"18818694","id":"PMC_18818694","title":"G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18818694","citation_count":319,"is_preprint":false},{"pmid":"26441991","id":"PMC_26441991","title":"Functional Role of G9a Histone Methyltransferase in Cancer.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26441991","citation_count":201,"is_preprint":false},{"pmid":"19144645","id":"PMC_19144645","title":"Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19144645","citation_count":164,"is_preprint":false},{"pmid":"23178591","id":"PMC_23178591","title":"Histone H3K9 methyltransferase G9a represses PPARγ expression and adipogenesis.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/23178591","citation_count":164,"is_preprint":false},{"pmid":"31270502","id":"PMC_31270502","title":"Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.","date":"2019","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31270502","citation_count":157,"is_preprint":false},{"pmid":"18809684","id":"PMC_18809684","title":"G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin tolerance.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18809684","citation_count":141,"is_preprint":false},{"pmid":"24322755","id":"PMC_24322755","title":"BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.","date":"2013","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/24322755","citation_count":129,"is_preprint":false},{"pmid":"28630300","id":"PMC_28630300","title":"G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28630300","citation_count":113,"is_preprint":false},{"pmid":"30535125","id":"PMC_30535125","title":"FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30535125","citation_count":107,"is_preprint":false},{"pmid":"19001366","id":"PMC_19001366","title":"Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19001366","citation_count":106,"is_preprint":false},{"pmid":"21149390","id":"PMC_21149390","title":"LSH and G9a/GLP complex are required for developmentally programmed DNA methylation.","date":"2010","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/21149390","citation_count":100,"is_preprint":false},{"pmid":"26320100","id":"PMC_26320100","title":"EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26320100","citation_count":91,"is_preprint":false},{"pmid":"28778944","id":"PMC_28778944","title":"Histone Methyltransferase G9a Is Required for Cardiomyocyte Homeostasis and Hypertrophy.","date":"2017","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/28778944","citation_count":90,"is_preprint":false},{"pmid":"31276898","id":"PMC_31276898","title":"Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31276898","citation_count":86,"is_preprint":false},{"pmid":"20334638","id":"PMC_20334638","title":"Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D.","date":"2010","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/20334638","citation_count":85,"is_preprint":false},{"pmid":"31775874","id":"PMC_31775874","title":"Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31775874","citation_count":82,"is_preprint":false},{"pmid":"31095524","id":"PMC_31095524","title":"CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis.","date":"2019","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/31095524","citation_count":82,"is_preprint":false},{"pmid":"24667637","id":"PMC_24667637","title":"Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24667637","citation_count":78,"is_preprint":false},{"pmid":"23112189","id":"PMC_23112189","title":"Maintenance of gene silencing by the coordinate action of the H3K9 methyltransferase G9a/KMT1C and the H3K4 demethylase Jarid1a/KDM5A.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23112189","citation_count":75,"is_preprint":false},{"pmid":"30747104","id":"PMC_30747104","title":"CNTN5-or EHMT2-human iPSC-derived neurons from individuals with autism develop hyperactive neuronal networks.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30747104","citation_count":73,"is_preprint":false},{"pmid":"28698370","id":"PMC_28698370","title":"G9a coordinates with the RPA complex to promote DNA damage repair and cell survival.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28698370","citation_count":70,"is_preprint":false},{"pmid":"26997278","id":"PMC_26997278","title":"Alternative Splicing of G9a Regulates Neuronal Differentiation.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26997278","citation_count":70,"is_preprint":false},{"pmid":"28443098","id":"PMC_28443098","title":"The Lysine Methyltransferase G9a in Immune Cell Differentiation and Function.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28443098","citation_count":67,"is_preprint":false},{"pmid":"29374157","id":"PMC_29374157","title":"Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29374157","citation_count":67,"is_preprint":false},{"pmid":"34383386","id":"PMC_34383386","title":"Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34383386","citation_count":67,"is_preprint":false},{"pmid":"34954891","id":"PMC_34954891","title":"EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/34954891","citation_count":60,"is_preprint":false},{"pmid":"26576615","id":"PMC_26576615","title":"EHMT2 directs DNA methylation for efficient gene silencing in mouse embryos.","date":"2015","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/26576615","citation_count":59,"is_preprint":false},{"pmid":"28135087","id":"PMC_28135087","title":"Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28135087","citation_count":58,"is_preprint":false},{"pmid":"35477569","id":"PMC_35477569","title":"An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35477569","citation_count":57,"is_preprint":false},{"pmid":"32269030","id":"PMC_32269030","title":"Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.","date":"2020","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/32269030","citation_count":57,"is_preprint":false},{"pmid":"25595900","id":"PMC_25595900","title":"Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25595900","citation_count":56,"is_preprint":false},{"pmid":"29053336","id":"PMC_29053336","title":"Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.","date":"2018","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29053336","citation_count":51,"is_preprint":false},{"pmid":"33113380","id":"PMC_33113380","title":"G9a Plays Distinct Roles in Maintaining DNA Methylation, Retrotransposon Silencing, and Chromatin Looping.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33113380","citation_count":51,"is_preprint":false},{"pmid":"27052169","id":"PMC_27052169","title":"G9a/GLP Complex Maintains Imprinted DNA Methylation in Embryonic Stem Cells.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27052169","citation_count":51,"is_preprint":false},{"pmid":"31432592","id":"PMC_31432592","title":"G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma.","date":"2019","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/31432592","citation_count":51,"is_preprint":false},{"pmid":"27452519","id":"PMC_27452519","title":"Human EHMT2/G9a activates p53 through methylation-independent mechanism.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27452519","citation_count":49,"is_preprint":false},{"pmid":"27174920","id":"PMC_27174920","title":"Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27174920","citation_count":47,"is_preprint":false},{"pmid":"33222246","id":"PMC_33222246","title":"Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/33222246","citation_count":46,"is_preprint":false},{"pmid":"23466651","id":"PMC_23466651","title":"Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.","date":"2013","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/23466651","citation_count":46,"is_preprint":false},{"pmid":"31647887","id":"PMC_31647887","title":"G9a promotes cell proliferation and suppresses autophagy in gastric cancer by directly activating mTOR.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31647887","citation_count":43,"is_preprint":false},{"pmid":"34685453","id":"PMC_34685453","title":"Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34685453","citation_count":41,"is_preprint":false},{"pmid":"34588438","id":"PMC_34588438","title":"SPOP mutation induces DNA methylation via stabilizing GLP/G9a.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34588438","citation_count":40,"is_preprint":false},{"pmid":"27229136","id":"PMC_27229136","title":"G9a promotes proliferation and inhibits cell cycle exit during myogenic differentiation.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27229136","citation_count":40,"is_preprint":false},{"pmid":"26688070","id":"PMC_26688070","title":"G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26688070","citation_count":40,"is_preprint":false},{"pmid":"32174799","id":"PMC_32174799","title":"EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32174799","citation_count":39,"is_preprint":false},{"pmid":"11707778","id":"PMC_11707778","title":"Novel NG36/G9a gene products encoded within the human and mouse MHC class III regions.","date":"2001","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/11707778","citation_count":38,"is_preprint":false},{"pmid":"29101051","id":"PMC_29101051","title":"Histone methyltransferase G9a modulates hepatic insulin signaling via regulating HMGA1.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29101051","citation_count":38,"is_preprint":false},{"pmid":"33347828","id":"PMC_33347828","title":"Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33347828","citation_count":37,"is_preprint":false},{"pmid":"35763668","id":"PMC_35763668","title":"Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35763668","citation_count":35,"is_preprint":false},{"pmid":"26198080","id":"PMC_26198080","title":"Regulation of cell differentiation and function by the euchromatin histone methyltranserfases G9a and GLP.","date":"2015","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/26198080","citation_count":35,"is_preprint":false},{"pmid":"33589432","id":"PMC_33589432","title":"G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33589432","citation_count":35,"is_preprint":false},{"pmid":"38065340","id":"PMC_38065340","title":"Galectin-7 Induction by EHMT2 Inhibition Enhances Immunity in Microsatellite Stability Colorectal Cancer.","date":"2023","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/38065340","citation_count":34,"is_preprint":false},{"pmid":"29745895","id":"PMC_29745895","title":"G9a regulates temporal preimplantation developmental program and lineage segregation in blastocyst.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/29745895","citation_count":34,"is_preprint":false},{"pmid":"36476474","id":"PMC_36476474","title":"PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.","date":"2022","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/36476474","citation_count":33,"is_preprint":false},{"pmid":"34775469","id":"PMC_34775469","title":"Emerging role of G9a in cancer stemness and promises as a therapeutic target.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34775469","citation_count":33,"is_preprint":false},{"pmid":"22704517","id":"PMC_22704517","title":"Protein kinase A determines timing of early differentiation through epigenetic regulation with G9a.","date":"2012","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/22704517","citation_count":33,"is_preprint":false},{"pmid":"29192276","id":"PMC_29192276","title":"Protein-lysine methyltransferases G9a and GLP1 promote responses to DNA damage.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29192276","citation_count":31,"is_preprint":false},{"pmid":"33938943","id":"PMC_33938943","title":"G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/33938943","citation_count":31,"is_preprint":false},{"pmid":"28977928","id":"PMC_28977928","title":"Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28977928","citation_count":31,"is_preprint":false},{"pmid":"31088968","id":"PMC_31088968","title":"EHMT2 and SETDB1 protect the maternal pronucleus from 5mC oxidation.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31088968","citation_count":29,"is_preprint":false},{"pmid":"32028644","id":"PMC_32028644","title":"EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32028644","citation_count":29,"is_preprint":false},{"pmid":"33147463","id":"PMC_33147463","title":"G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33147463","citation_count":29,"is_preprint":false},{"pmid":"36971192","id":"PMC_36971192","title":"G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells.","date":"2023","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/36971192","citation_count":28,"is_preprint":false},{"pmid":"28662962","id":"PMC_28662962","title":"Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.","date":"2017","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28662962","citation_count":28,"is_preprint":false},{"pmid":"31141392","id":"PMC_31141392","title":"Insights for the design of protein lysine methyltransferase G9a inhibitors.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31141392","citation_count":27,"is_preprint":false},{"pmid":"27239264","id":"PMC_27239264","title":"The lysine methyltransferase Ehmt2/G9a is dispensable for skeletal muscle development and regeneration.","date":"2016","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/27239264","citation_count":27,"is_preprint":false},{"pmid":"29337058","id":"PMC_29337058","title":"EHMT2 is a metastasis regulator in breast cancer.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29337058","citation_count":27,"is_preprint":false},{"pmid":"30718920","id":"PMC_30718920","title":"Cyclin D1 integrates G9a-mediated histone methylation.","date":"2019","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30718920","citation_count":26,"is_preprint":false},{"pmid":"28327608","id":"PMC_28327608","title":"KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28327608","citation_count":26,"is_preprint":false},{"pmid":"28455378","id":"PMC_28455378","title":"G9a controls placental vascular maturation by activating the Notch Pathway.","date":"2017","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28455378","citation_count":26,"is_preprint":false},{"pmid":"27417236","id":"PMC_27417236","title":"G9a inhibition induced PKM2 regulates autophagic responses.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27417236","citation_count":26,"is_preprint":false},{"pmid":"36272457","id":"PMC_36272457","title":"G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation.","date":"2022","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/36272457","citation_count":25,"is_preprint":false},{"pmid":"36604593","id":"PMC_36604593","title":"ZFP462 safeguards neural lineage specification by targeting G9A/GLP-mediated heterochromatin to silence enhancers.","date":"2023","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36604593","citation_count":24,"is_preprint":false},{"pmid":"27174055","id":"PMC_27174055","title":"G9a - An Appealing Antineoplastic Target.","date":"2017","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/27174055","citation_count":24,"is_preprint":false},{"pmid":"34619147","id":"PMC_34619147","title":"Heterodimerization of H3K9 histone methyltransferases G9a and GLP activates methyl reading and writing capabilities.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34619147","citation_count":23,"is_preprint":false},{"pmid":"28596979","id":"PMC_28596979","title":"The expanding role of the Ehmt2/G9a complex in neurodevelopment.","date":"2017","source":"Neurogenesis (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/28596979","citation_count":22,"is_preprint":false},{"pmid":"33252038","id":"PMC_33252038","title":"EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33252038","citation_count":21,"is_preprint":false},{"pmid":"27081761","id":"PMC_27081761","title":"Depletion of G9a gene induces cell apoptosis in human gastric carcinoma.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27081761","citation_count":21,"is_preprint":false},{"pmid":"33088284","id":"PMC_33088284","title":"Hypoxia-Inducible Lysine Methyltransferases: G9a and GLP Hypoxic Regulation, Non-histone Substrate Modification, and Pathological Relevance.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33088284","citation_count":19,"is_preprint":false},{"pmid":"33277444","id":"PMC_33277444","title":"The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33277444","citation_count":19,"is_preprint":false},{"pmid":"34830365","id":"PMC_34830365","title":"Histone Methyltransferases SUV39H1 and G9a and DNA Methyltransferase DNMT1 in Penumbra Neurons and Astrocytes after Photothrombotic Stroke.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34830365","citation_count":19,"is_preprint":false},{"pmid":"28527696","id":"PMC_28527696","title":"Essential roles of G9a in cell proliferation and differentiation during tooth development.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28527696","citation_count":18,"is_preprint":false},{"pmid":"28644763","id":"PMC_28644763","title":"Methyltransferase G9A Regulates Osteogenesis via Twist Gene Repression.","date":"2017","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/28644763","citation_count":18,"is_preprint":false},{"pmid":"37402853","id":"PMC_37402853","title":"HMGB1 neuroimmune signaling and REST-G9a gene repression contribute to ethanol-induced reversible suppression of the cholinergic neuron phenotype.","date":"2023","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/37402853","citation_count":17,"is_preprint":false},{"pmid":"35149587","id":"PMC_35149587","title":"Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35149587","citation_count":17,"is_preprint":false},{"pmid":"34344448","id":"PMC_34344448","title":"EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.","date":"2021","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/34344448","citation_count":17,"is_preprint":false},{"pmid":"36896891","id":"PMC_36896891","title":"Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.","date":"2023","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36896891","citation_count":16,"is_preprint":false},{"pmid":"38814866","id":"PMC_38814866","title":"EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38814866","citation_count":16,"is_preprint":false},{"pmid":"37307824","id":"PMC_37307824","title":"G9a Inhibition Promotes Neuroprotection through GMFB Regulation in Alzheimer's Disease.","date":"2024","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/37307824","citation_count":16,"is_preprint":false},{"pmid":"30710318","id":"PMC_30710318","title":"Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss.","date":"2019","source":"Journal of the Association for Research in Otolaryngology : JARO","url":"https://pubmed.ncbi.nlm.nih.gov/30710318","citation_count":16,"is_preprint":false},{"pmid":"35641480","id":"PMC_35641480","title":"Calreticulin enhances gastric cancer metastasis by dimethylating H3K9 in the E-cadherin promoter region mediating by G9a.","date":"2022","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35641480","citation_count":16,"is_preprint":false},{"pmid":"34681949","id":"PMC_34681949","title":"EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34681949","citation_count":15,"is_preprint":false},{"pmid":"39810240","id":"PMC_39810240","title":"Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma.","date":"2025","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/39810240","citation_count":15,"is_preprint":false},{"pmid":"30867409","id":"PMC_30867409","title":"SUMOylation of G9a regulates its function as an activator of myoblast proliferation.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30867409","citation_count":15,"is_preprint":false},{"pmid":"38285887","id":"PMC_38285887","title":"Targeting G9a/DNMT1 methyltransferase activity impedes IGF2-mediated survival in hepatoblastoma.","date":"2024","source":"Hepatology communications","url":"https://pubmed.ncbi.nlm.nih.gov/38285887","citation_count":14,"is_preprint":false},{"pmid":"34013595","id":"PMC_34013595","title":"The histone methyltransferase G9a mediates stress-regulated alcohol drinking.","date":"2021","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/34013595","citation_count":14,"is_preprint":false},{"pmid":"36072299","id":"PMC_36072299","title":"Cholinergic REST-G9a gene repression through HMGB1-TLR4 neuroimmune signaling regulates basal forebrain cholinergic neuron phenotype.","date":"2022","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36072299","citation_count":14,"is_preprint":false},{"pmid":"34519223","id":"PMC_34519223","title":"H3K9 methyltransferase EHMT2/G9a controls ERVK-driven noncanonical imprinted genes.","date":"2021","source":"Epigenomics","url":"https://pubmed.ncbi.nlm.nih.gov/34519223","citation_count":13,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50368,"output_tokens":10136,"usd":0.151572,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20590,"output_tokens":5032,"usd":0.114375,"stage2_stop_reason":"end_turn"},"total_usd":0.265947,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2011,\n      \"finding\": \"G9a and GLP exist predominantly as a G9a-GLP heteromeric complex that is the primary functional H3K9 methyltransferase in vivo, responsible for H3K9me1 and H3K9me2 in euchromatin.\",\n      \"method\": \"Biochemical characterization, genetic knockout studies in mammalian cells\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs, foundational finding supported by genetic KO and biochemical complex characterization\",\n      \"pmids\": [\"21498567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EHMT2/G9a directly binds DNMT1 both in vivo and in vitro, colocalizes with DNMT1 at replication foci during DNA replication, and together with DNMT1 forms a ternary complex with PCNA on chromatin; this complex enhances both DNA and H3K9 methylation of in vitro assembled chromatin substrates.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, colocalization studies, siRNA knockdown, in vitro chromatin methylation assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP, in vitro reconstitution, functional chromatin methylation assay, siRNA knockdown with defined mechanistic readout\",\n      \"pmids\": [\"17085482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"G9a/GLP complex suppresses transcription by independently inducing both H3K9 methylation and DNA methylation; catalytically inactive G9a/GLP mutants fail to rescue H3K9 methylation but still support DNA methylation-dependent gene silencing, demonstrating two distinct silencing mechanisms.\",\n      \"method\": \"ES cell catalytic mutant analysis, DNA methyltransferase inhibitor treatment, gene expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — catalytic mutant reconstitution in ES cells with multiple orthogonal readouts (H3K9me, DNA methylation, gene expression)\",\n      \"pmids\": [\"18818694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"G9a/KMT1C mediates mono- and dimethylation of histone H1.4 at lysine 26 (H1.4K26) in vitro and in vivo, providing a recognition surface for HP1 and L3MBTL1; G9a also promotes H1 deposition and is required for retention of H1 on chromatin.\",\n      \"method\": \"In vitro methyltransferase assay, in vivo ChIP, H1.4K26 methylation-specific antibodies, H1 chromatin retention assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro enzymatic assay plus in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"19144645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"G9a/KMT1C and GLP1/KMT1D methylate histone H1.2 at lysine 187 (H1.2K187) in its C-terminus in vitro and in vivo; this methylation is variant-specific and distinct from H1.4K26 methylation in that it cannot recruit HP1 and is not reversed by JMJD2D/KDM4.\",\n      \"method\": \"In vitro methyltransferase assay, in vivo cell-based methylation analysis, HP1 binding assays, cell cycle analysis\",\n      \"journal\": \"Epigenetics & chromatin\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro and in vivo enzymatic assays with functional downstream reader analysis\",\n      \"pmids\": [\"20334638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"G9a binds the TNFα promoter in endotoxin-tolerant cells, dimethylates H3K9 creating a platform for HP1 binding, which recruits DNMT3a/b causing promoter CpG methylation and transcriptional silencing; G9a knockdown disrupts this silencing cascade.\",\n      \"method\": \"ChIP, RNA interference/siRNA knockdown, CpG methylation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and siRNA knockdown with defined mechanistic pathway, single lab\",\n      \"pmids\": [\"18809684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"LSH (encoded by Hells) is required for G9a/GLP complex recruitment to specific loci; in Hells-/- MEFs, G9a recruitment is compromised, impairing stable gene silencing and DNA methylation at specific promoters through a cooperative LSH–G9a/GLP mechanism.\",\n      \"method\": \"Genome-wide DNA methylation profiling, ChIP, Hells knockout MEFs\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide profiling plus ChIP in genetic KO model, single lab\",\n      \"pmids\": [\"21149390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"G9a functions within two distinct protein complexes: one containing the coactivator Mediator (for gene activation) and one containing the H3K4 demethylase Jarid1a/KDM5A (for gene repression); repressive function requires coordinate action of G9a-mediated H3K9me2/H3K27me2 and Jarid1a-mediated removal of H3K4me3.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, genetic analysis in erythroid differentiation model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reciprocal Co-IP and ChIP, single lab, two orthogonal methods\",\n      \"pmids\": [\"23112189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"G9a mediates H3K9 dimethylation and DNA methylation at the Oct3/4 and Nanog promoters downstream of protein kinase A (PKA) signaling; G9a deletion abolishes PKA-driven acceleration of ESC differentiation, placing G9a as a PKA effector controlling differentiation timing.\",\n      \"method\": \"G9a knockout ESC/mouse model, PKA activation experiments, ChIP, bisulfite sequencing\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with phenotypic rescue, ChIP and DNA methylation analysis, signaling epistasis established\",\n      \"pmids\": [\"22704517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EHMT2 binds specific genomic loci in embryonic cells (including CpG-rich promoters of germline-specific genes), is marked by H3K9me2, and is required for DNA methylation at these loci; EHMT2-mediated DNA methylation is instrumental for gene silencing at these loci during embryogenesis.\",\n      \"method\": \"Ehmt2 knockout mouse model, genome-wide DNA methylation analysis, ChIP\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with genome-wide methylation profiling and ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"26576615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G9a exists as two isoforms distinguished by alternative splicing of exon 10 (E10); E10 inclusion increases G9a nuclear localization and overall H3K9me2 levels without affecting catalytic activity, and the E10+ isoform is necessary for neuronal differentiation; G9a promotes E10 inclusion creating a positive feedback loop.\",\n      \"method\": \"Alternative splicing analysis, nuclear/cytoplasmic fractionation, H3K9me2 measurement, neuronal differentiation assays, G9a knockdown\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — subcellular fractionation tied to functional consequence, differentiation assays, single lab\",\n      \"pmids\": [\"26997278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G9a blocks myogenic cell cycle exit via methylation-dependent transcriptional repression of p21(Cip/Waf1) and Rb1 (MyoD target genes), and activates E2F1-target genes in a methyltransferase activity-independent manner by associating with the E2F1/PCAF complex to enhance PCAF occupancy and histone acetylation at E2F1-target promoters.\",\n      \"method\": \"ChIP, Co-immunoprecipitation, G9a knockdown, transcriptome analysis, cell cycle assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP with functional KD, single lab, two orthogonal mechanisms defined\",\n      \"pmids\": [\"27229136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In response to DNA double-strand breaks, G9a is phosphorylated at serine 211 by casein kinase 2 (CK2), recruited to chromatin, and directly interacts with the replication protein A (RPA) complex to promote RPA and Rad51 loading at DSBs, facilitating homologous recombination repair.\",\n      \"method\": \"Phosphorylation mapping, Co-immunoprecipitation, RPA foci formation assays, HR repair assays, CK2 inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — phosphorylation site identification, reciprocal Co-IP with RPA, functional HR assay, multiple orthogonal methods\",\n      \"pmids\": [\"28698370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ATM phosphorylates G9a on serine 569, which is required for its recruitment to DNA breaks; G9a catalytic activity is required for early recruitment of DNA repair factors 53BP1 and BRCA1 to DNA breaks.\",\n      \"method\": \"Phosphorylation site mutation, DNA damage foci analysis, G9a catalytic inhibition, ionizing radiation sensitivity assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — phosphorylation mapping and foci assays, single lab\",\n      \"pmids\": [\"29192276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"G9a protein stability is increased under hypoxia via reduced proline hydroxylation leading to inefficient proteasomal degradation, resulting in increased H3K9me2 at target promoters and repression of specific genes.\",\n      \"method\": \"Protein stability assays, proline hydroxylation analysis, proteasome inhibition, ChIP, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — mechanistic dissection of post-translational stability, ChIP, single lab\",\n      \"pmids\": [\"28630300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"G9a forms a complex with MEF2C transcription factor in cardiomyocytes and represses key cardiac function genes via H3K9me2; G9a also interacts with EZH2 (PRC2 catalytic subunit) and is required for maintenance of heterochromatin and silencing of developmental genes in the adult heart.\",\n      \"method\": \"Conditional cardiac-specific G9a KO mouse, ChIP-seq, RNA-seq, Co-immunoprecipitation\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with ChIP-seq and RNA-seq plus Co-IP, multiple orthogonal methods\",\n      \"pmids\": [\"28778944\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G9a methylates FOXO1 at K273 in vitro and in vivo; this methylation increases FOXO1 interaction with E3 ligase SKP2, decreasing FOXO1 protein stability and promoting colon cancer cell proliferation; insulin increases G9a expression, resulting in insulin-mediated FOXO1 degradation via K273 methylation.\",\n      \"method\": \"In vitro methylation assay, Co-immunoprecipitation, protein stability assay, proliferation and apoptosis assays\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzymatic assay, Co-IP for reader interaction, functional cell assays, single lab\",\n      \"pmids\": [\"30535125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"G9a (EHMT2) promotes H3K27 methylation by upregulating PCL3 (increasing PRC2 promoter recruitment) and downregulating H3K27 demethylase KDM7A; G9a physically interacts with EZH2 to repress E-cadherin expression and induce EMT in pancreatic cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, siRNA knockdown, overexpression experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP with functional knockdown, single lab\",\n      \"pmids\": [\"26688070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G9a interacts with human G9a (hG9a) but unlike mouse G9a, human G9a potently stimulates p53 transcriptional activity independent of its methyltransferase activity; hG9a interacts with histone acetyltransferase p300/CBP resulting in increased histone acetylation at the Puma promoter.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, luciferase reporter, shRNA knockdown, apoptosis and colony assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP, single lab, human vs. mouse orthologue distinction made\",\n      \"pmids\": [\"27452519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SUMOylation of G9a at K79, K152, K256, and K799 is required for its function as an activator of myoblast proliferation; SUMOylation acts as a signal for PCAF recruitment at E2F1-target genes, increasing H3K9 acetylation and S-phase progression, but does not affect G9a-mediated repression of MyoD activity.\",\n      \"method\": \"SUMOylation site mutagenesis, complementation assays in G9a conditional KO primary myoblasts, ChIP, cell cycle analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — site-specific mutagenesis, genetic complementation in primary KO cells, ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"30867409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EHMT2/G9a and EZH2 physically interact with each other at the CXCL10 promoter in IPF fibroblasts; EZH2 knockdown reduces G9a and H3K9me3, and G9a knockdown reduces EZH2 and H3K27me3, demonstrating a functionally interdependent interplay mediating epigenetic repression of CXCL10.\",\n      \"method\": \"ChIP, Re-ChIP, proximity ligation assay, siRNA knockdown\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — proximity ligation assay and ChIP, single lab, two orthogonal methods\",\n      \"pmids\": [\"29053336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G9a promotes H3K9me2-dependent silencing of pro-inflammatory cytokines (including TNF) in recurrent mammary tumors; G9a-mediated silencing suppresses necroptosis and tumor recurrence.\",\n      \"method\": \"G9a genetic ablation, ChIP, gene expression analysis, cell death assays in recurrent tumor models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic ablation with ChIP and functional cell death readout, single lab\",\n      \"pmids\": [\"33147463\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"G9a regulates chromatin accessibility, epigenetic modifications, and transcriptional silencing in both catalytic-dependent and catalytic-independent manners; loss of G9a leads to altered CTCF and cohesin binding and differential chromatin looping, especially at retrotransposons, while topologically associated domains are largely unaffected.\",\n      \"method\": \"G9a depletion and catalytic mutant ESC lines, ATAC-seq, ChIP-seq, RNA-seq, Hi-C\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genome-wide orthogonal approaches in catalytic mutant plus depletion models\",\n      \"pmids\": [\"33113380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"G9a gain-of-function mutations and copy number gains in melanoma suppress WNT antagonist DKK1 expression through H3K9me2-mediated promoter methylation, activating WNT/β-catenin signaling and driving tumor growth and immune exclusion.\",\n      \"method\": \"Oncogenic G9a mutation identification, ChIP, genetic/pharmacologic G9a suppression in vitro and in vivo tumor models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and genetic/pharmacologic inhibition with in vivo models, single study\",\n      \"pmids\": [\"32269030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SPOP E3 ligase binds GLP and promotes its polyubiquitination and proteasomal degradation; SPOP mutation stabilizes GLP and its partner G9a, leading to aberrant global DNA hypermethylation and silencing of tumor suppressor genes in prostate cancer.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SPOP mutant cell lines, genome-wide DNA methylome analysis, xenograft models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP, ubiquitination assay, genome-wide methylome, in vivo models, multiple orthogonal methods\",\n      \"pmids\": [\"34588438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Heterodimerization of G9a and GLP (heterodimer) significantly enhances both H3K9me2 reading (recognition) and writing (catalytic turnover) activities compared to homodimers; the heterodimer shows ~10-fold increased turnover on nucleosomal substrates; cross-linking mass spectrometry reveals distinct domain contacts between heterodimer vs. homodimers suggesting relieved autoinhibition.\",\n      \"method\": \"Recombinant homodimer/heterodimer production, in vitro methyltransferase assay, nucleosomal substrate assay, cross-linking mass spectrometry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with defined dimers, nucleosomal substrates, cross-linking MS structural analysis\",\n      \"pmids\": [\"34619147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"G9a/GLP complex maintains imprinted DNA methylation at imprinting control regions (ICRs) in ESCs through a catalytic activity-independent mechanism; the complex protects imprinted DNA methylation by recruiting de novo DNA methyltransferases that antagonize TET dioxygenase-dependent erosion, not through H3K9me2.\",\n      \"method\": \"G9a/GLP knockout and catalytic mutant ESCs, allele-specific DNA methylation analysis, TET dioxygenase assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO plus catalytic mutant with allele-specific methylation, multiple orthogonal approaches\",\n      \"pmids\": [\"27052169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EHMT2 and SETDB1 in oocytes provide H3K9me2 and H3K9me3, respectively, to the maternal pronucleus; genetic deletion of the EHMT2 catalytic domain in oocytes reduces H3K9me2 and increases TET3-mediated 5mC oxidation (5hmC, 5fC, 5caC) in the maternal pronucleus, demonstrating that oocyte-derived EHMT2 H3K9 methylation protects maternal DNA from oxidative demethylation.\",\n      \"method\": \"Oocyte-specific conditional KO of EHMT2 catalytic domain, immunofluorescence for 5mC/5hmC/5fC/5caC in zygotes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic catalytic domain deletion in oocytes with functional 5mC oxidation readout, direct epistasis\",\n      \"pmids\": [\"31088968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G9a (EHMT2) is required for TGFβ- and matrix stiffness-induced fibroblast activation; G9a and CBX5 (HP1α) form a repressor complex that deposits H3K9me marks to silence PPARGC1A (PGC1α) expression, sustaining fibroblast activation in pulmonary fibrosis.\",\n      \"method\": \"G9a inhibition and knockdown, ChIP, TGFβ and mechanical stiffness stimulation, bleomycin lung injury model\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and genetic/pharmacologic inhibition in primary cells and in vivo model, single lab\",\n      \"pmids\": [\"31095524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"G9a activates the Notch pathway in placental endothelial progenitors to balance endothelial and trophoblast proliferation; G9a-deficient endothelial progenitors show downregulated Notch effectors including Rbpj, and Notch pathway activation rescues placental vascular defects.\",\n      \"method\": \"Conditional G9a KO in endothelial progenitors, in vivo vascular analysis, Notch activation rescue experiments\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional genetic KO with pathway rescue, in vivo model, single lab\",\n      \"pmids\": [\"28455378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZFP462 (murine homologue of ZNF462) recruits the G9A/GLP complex to transposable element-containing enhancers harbouring pluripotency and meso-endoderm transcription factor binding sites, seeding heterochromatin to restrict transcription factor binding and silence meso-endodermal genes during neural lineage specification.\",\n      \"method\": \"ZFP462 screen and KO in ESCs, ChIP-seq, ATAC-seq, Co-IP showing ZFP462-G9A/GLP interaction\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP plus genome-wide ChIP-seq and ATAC-seq in genetic KO model, multiple orthogonal methods\",\n      \"pmids\": [\"36604593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PALI1 interacts with G9A and bridges formation of a G9A-PALI1-PRC2 super-complex that occupies a subset of G9A-target genes to mediate dual H3K9/K27 methylation and gene repression, promoting prostate cancer cell proliferation and invasion.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, genetic knockdown, in vitro and xenograft tumor models\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP for complex formation, ChIP-seq for genomic occupancy, functional in vivo models\",\n      \"pmids\": [\"36476474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cyclin D1 directly associates with G9a and is required for G9a recruitment to target gene chromatin and for G9a-induced H3K9me2; cyclin D1 is also required for nuclear lamina-lamina-associated domain (LAD) interactions dependent on G9a-mediated H3K9me2.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, cyclin D1 genetic requirement assays, LAD interaction analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP, single lab, two orthogonal methods\",\n      \"pmids\": [\"30718920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"NG36 and G9a are expressed as a single ~3.9 kb transcript in human and mouse cells; the full-length NG36/G9a protein is concentrated exclusively in the nucleus, whereas the G9a region alone (aa 210-1210) localizes to both cytoplasm and nucleus and is marginalized at the nuclear periphery—demonstrating that the NG36 domain controls nuclear localization of the protein.\",\n      \"method\": \"Expression cloning, T7-epitope tagged subcellular localization in transiently transfected mammalian cells, RT-PCR for splice variants\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct subcellular localization experiment with domain deletion, but single lab and no functional readout beyond localization\",\n      \"pmids\": [\"11707778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"G9a directly binds and methylates GMFB (glia maturation factor β) at lysine 20 and K25 in vitro; methylation at K25 suppresses GMFB neuroprotective activity; G9a pharmacological inhibition removes K25 methylation, increasing GMFB activity and promoting neuroprotective effects in Alzheimer's disease models.\",\n      \"method\": \"In vitro methylation assay identifying K20 and K25, ChIP-seq after G9a inhibition, pharmacological inhibition in mouse model and C. elegans\",\n      \"journal\": \"Aging and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–3 / Moderate — in vitro methylation assay identifying sites, in vivo ChIP-seq, but limited mutagenesis validation in vivo\",\n      \"pmids\": [\"37307824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"G9a promotes mTOR expression through H3K9 monomethylation at the mTOR promoter (not dimethylation); G9a knockdown decreases H3K9 monomethylation at the mTOR promoter and reduces mTOR expression, thereby suppressing gastric cancer cell proliferation and inducing autophagy.\",\n      \"method\": \"ChIP analysis of H3K9me1/me2 at mTOR promoter, G9a siRNA and inhibitor treatment, mTOR rescue experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP with functional rescue, single lab\",\n      \"pmids\": [\"31647887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EHMT2 controls H3K9me2 at ERVK (endogenous retrovirus K) promoters on the maternal allele of noncanonical imprinted genes in the ectoplacental cone; in Ehmt2 embryos, loss of H3K9me2 and DNA methylation at ERVK promoters leads to biallelic derepression of noncanonical imprinted genes.\",\n      \"method\": \"Allele-specific RNA-seq in Ehmt2 KO embryos, reciprocal mouse crosses, ERVK promoter methylation analysis\",\n      \"journal\": \"Epigenomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — allele-specific RNA-seq in genetic KO with DNA methylation analysis, single lab\",\n      \"pmids\": [\"34519223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G9a binds the Fbxw7 promoter and represses its transcription via H3K9me2, thereby activating the Notch pathway and promoting stemness in glioma stem cells and an immunosuppressive tumor microenvironment.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, G9a inhibition/knockdown, flow cytometry for immune cells in orthotopic model\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP and luciferase reporter validation of direct promoter interaction, single lab\",\n      \"pmids\": [\"36971192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CHD4 represses galectin-7 expression by recruiting EHMT2 to form a co-transcriptional silencing complex; EHMT2 inhibition disrupts this complex, inducing galectin-7 expression and converting immunosuppressive MSS colorectal cancer to an immunomodulatory state.\",\n      \"method\": \"CRISPR screen, co-immunoprecipitation, ChIP, functional immune co-culture assays\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and ChIP with CRISPR screen validation, single lab\",\n      \"pmids\": [\"38065340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EHMT2 directly mediates H3K9me2 methylation of the APC promoter to epigenetically silence APC expression, activating Wnt-β-catenin signaling in hepatocellular carcinoma.\",\n      \"method\": \"EHMT2 CRISPR KO, ChIP for H3K9me2 at APC promoter, rescue experiments with APC overexpression, xenograft assays\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP with genetic rescue and functional KO, single lab\",\n      \"pmids\": [\"34344448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"c-Myc interacts with G9a in HCC, cooperating to regulate c-Myc-dependent gene repression; G9a stabilizes c-Myc protein to promote cancer growth and invasion.\",\n      \"method\": \"Co-immunoprecipitation, c-Myc/G9a co-expression knockdown and overexpression, xenograft and patient-derived xenograft models\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP with functional in vivo models, single lab\",\n      \"pmids\": [\"36896891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EHMT2 increases methylation of the SFRP1 promoter region, reducing SFRP1 expression and activating the WNT/β-catenin pathway to drive neuroendocrine transformation and TKI resistance in lung adenocarcinoma.\",\n      \"method\": \"ChIP for H3K9me2/DNA methylation at SFRP1 promoter, EHMT2 inhibitor rescue, CDX mouse models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — ChIP with in vivo rescue model, single lab\",\n      \"pmids\": [\"38814866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Discovery of first-in-class covalent G9a/GLP inhibitors targeting a cysteine at the substrate binding site; X-ray crystallography confirmed covalent binding mode; compound 8 (MS8511) showed improved potency over noncovalent inhibitor UNC0642 and potential kinetic preference for G9a over GLP.\",\n      \"method\": \"Covalent inhibitor synthesis, enzymatic assay, mass spectrometry-based covalent modification confirmation, X-ray crystallography, cellular H3K9me2 assay\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — X-ray crystal structure with MS covalent modification confirmation and enzymatic assay, single lab\",\n      \"pmids\": [\"35763668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"G9a inhibition in the nucleus accumbens (NAc) blocks stress-regulated changes in ethanol drinking including kappa-opioid receptor-stimulated potentiation of alcohol drinking, demonstrating that NAc G9a is specifically required for stress-regulated (not baseline) alcohol drinking behavior.\",\n      \"method\": \"Viral-mediated G9a knockdown in NAc, chronic intermittent ethanol (CIE) mouse model, pharmacological G9a inhibition\",\n      \"journal\": \"Addiction biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — region-specific viral KD with behavioral readout, single lab\",\n      \"pmids\": [\"34013595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"G9a-mediated H3K9me2 in naive T cells restricts Th17 and Treg differentiation by limiting chromatin accessibility and TGF-β1 responsiveness; H3K9me2 is lost upon T cell activation, and G9a loss increases chromatin accessibility and TGF-β1 sensitivity to promote Th17/Treg differentiation.\",\n      \"method\": \"T cell-specific G9a KO mice, T cell transfer colitis model, in vitro differentiation assays, ChIP for H3K9me2, ATAC-seq/chromatin accessibility\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic T cell-specific KO with in vivo model and ChIP, multiple orthogonal methods\",\n      \"pmids\": [\"24667637\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EHMT2/G9a is a SET domain histone lysine methyltransferase that functions primarily as a heterodimer with GLP to catalyze H3K9me1 and H3K9me2 in euchromatin (heterodimerization enhancing both reading and writing ~10-fold over homodimers); it directly binds DNMT1 and PCNA at replication forks to coordinate H3K9 and DNA methylation, methylates non-histone substrates including H1.4K26, H1.2K187, FOXO1-K273, and GMFB-K25 to regulate their stability or activity, is recruited to DNA double-strand breaks via CK2-mediated phosphorylation at Ser211 to promote RPA/Rad51 loading and homologous recombination, and is regulated by SUMOylation (activating its co-activator function at E2F1 targets), prolyl hydroxylation (controlling proteasomal stability under hypoxia), and SPOP-mediated ubiquitination of its partner GLP; it additionally functions as a scaffold (independently of catalytic activity) in complexes with Mediator, PCAF, MEF2C, ZFP462, CHD4, and PALI1-PRC2 to control transcriptional programs in development, immune differentiation, DNA repair, and cancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EHMT2 (G9a) is a SET-domain histone lysine methyltransferase that operates predominantly as a G9a-GLP heterodimer, the principal enzyme generating H3K9me1 and H3K9me2 in euchromatin [#0]; heterodimerization relieves autoinhibition and enhances both H3K9me2 recognition and catalytic turnover roughly 10-fold over homodimers on nucleosomes [#25]. It couples H3K9 methylation to DNA methylation by binding DNMT1 and forming a ternary complex with PCNA at replication foci, and by establishing H3K9me2/HP1 platforms that recruit de novo DNA methyltransferases to silence target promoters [#1, #5]; catalytic and DNA-methylation-dependent silencing are mechanistically separable, and several G9a functions—including protection of imprinted DNA methylation and transcriptional co-activation—are independent of its catalytic activity [#2, #26]. Through these activities G9a controls developmental and lineage programs, silencing germline, meso-endodermal, and cardiac genes and protecting maternal and imprinted DNA from TET-mediated demethylation [#9, #15, #27, #30], and restraining Th17/Treg differentiation in naive T cells [#44]. Beyond histones, G9a methylates non-histone substrates including histone H1 variants (H1.4K26, H1.2K187), FOXO1-K273 to drive its SKP2-dependent degradation, and GMFB-K25 [#3, #4, #16, #34]. G9a is regulated by signaling and post-translational modification: CK2- and ATM-dependent phosphorylation recruit it to DNA double-strand breaks to promote RPA/Rad51 loading and homologous recombination [#12, #13], SUMOylation activates its PCAF-dependent co-activator function at E2F1 targets [#19], prolyl hydroxylation controls its stability under hypoxia [#14], and SPOP-mediated ubiquitination of its partner GLP governs heterodimer abundance [#24]. It further acts as a scaffold within complexes containing Mediator, EZH2/PRC2 (via PALI1), CHD4, MEF2C, and ZFP462 to coordinate H3K9 and H3K27 methylation and shape transcriptional programs in development and cancer [#7, #15, #30, #31, #38]. In tumors G9a drives oncogenic programs by silencing WNT antagonists (DKK1, APC, SFRP1) and tumor suppressors and by stabilizing c-Myc [#23, #39, #40, #41].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that the full-length protein is exclusively nuclear and identified a domain controlling its nuclear localization, defining where G9a acts.\",\n      \"evidence\": \"Epitope-tagged subcellular localization with domain deletion in transfected mammalian cells\",\n      \"pmids\": [\"11707778\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional readout beyond localization\", \"Single lab\", \"NLS not mapped at residue level\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed G9a physically links H3K9 methylation to the DNA replication and methylation machinery, answering how the two epigenetic marks are coordinated.\",\n      \"evidence\": \"Reciprocal Co-IP, in vitro binding, replication foci colocalization, in vitro chromatin methylation assay\",\n      \"pmids\": [\"17085482\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and order of complex assembly at forks unresolved\", \"Direct vs DNMT1-bridged PCNA contact not fully separated\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrated G9a silences genes through two separable routes—H3K9 methylation and DNA methylation—revealing a catalytic-independent silencing arm.\",\n      \"evidence\": \"Catalytic-inactive mutant reconstitution in ES cells with DNMT inhibitor and expression readouts; ChIP/siMethylation in tolerant cells\",\n      \"pmids\": [\"18818694\", \"18809684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic-independent DNA methylation recruitment mechanism not defined\", \"TNFa promoter cascade from single lab\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified histone H1 variants as direct G9a substrates, extending its writing activity beyond core histones and defining variant-specific reader outcomes.\",\n      \"evidence\": \"In vitro and in vivo methyltransferase assays with site-specific antibodies and HP1/L3MBTL1 binding analysis\",\n      \"pmids\": [\"19144645\", \"20334638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo functional consequences of H1.2K187 methylation limited\", \"Cooperativity with histone substrate methylation unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed G9a within distinct activating (Mediator) and repressive (Jarid1a) complexes and as a PKA effector controlling differentiation timing, showing context-dependent dual function.\",\n      \"evidence\": \"Co-IP, ChIP, genetic erythroid model; G9a KO ESC with PKA activation and epistasis\",\n      \"pmids\": [\"23112189\", \"22704517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Switch between activating and repressive complexes not mechanistically defined\", \"Mediator-G9a interface unmapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Confirmed genome-wide that G9a directs DNA methylation and silencing at germline-gene promoters in embryos and interacts with EZH2 to drive EMT, linking H3K9 and H3K27 pathways.\",\n      \"evidence\": \"Ehmt2 KO mouse with genome-wide methylation and ChIP; Co-IP/ChIP in pancreatic cancer cells\",\n      \"pmids\": [\"26576615\", \"26688070\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect EZH2 cooperation not separated\", \"Locus-selection determinants unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Revealed catalytic-independent and isoform-dependent layers: protection of imprinted DNA methylation without H3K9me2, splice-driven nuclear localization, and human-specific p53 co-activation.\",\n      \"evidence\": \"G9a/GLP KO and catalytic-mutant ESCs with allele-specific methylation; alternative splicing/fractionation; Co-IP and reporter assays for p53/p300\",\n      \"pmids\": [\"27052169\", \"26997278\", \"27452519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which the complex recruits de novo DNMTs catalytically-independently unresolved\", \"Species divergence in p53 regulation unexplained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established G9a as a phosphorylation-regulated DNA repair factor and defined post-translational and complex-based controls over its stability and tissue function.\",\n      \"evidence\": \"CK2/ATM phospho-site mapping, RPA/Rad51 and 53BP1/BRCA1 foci, HR assays; prolyl hydroxylation stability assays; cardiac conditional KO with ChIP-seq/RNA-seq and MEF2C/EZH2 Co-IP; Notch rescue in placenta\",\n      \"pmids\": [\"28698370\", \"29192276\", \"28630300\", \"28778944\", \"28455378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DSB recruitment requires catalytic activity vs scaffolding partly conflicting\", \"Substrates methylated at break sites not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Expanded the non-histone substrate and regulatory repertoire (FOXO1-K273 degradation, SUMO-driven PCAF co-activation) and detailed fibrosis and chromatin-loop functions.\",\n      \"evidence\": \"In vitro methylation and SKP2 Co-IP; SUMO site mutagenesis with myoblast complementation and ChIP; cyclin D1 Co-IP/ChIP/LAD analysis; G9a-CBX5 ChIP in fibrosis models; EZH2 interplay by PLA/Re-ChIP\",\n      \"pmids\": [\"30535125\", \"30867409\", \"30718920\", \"31095524\", \"29053336\", \"31088968\", \"31647887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of non-histone methylation across tissues untested\", \"How SUMO toggles activator vs repressor states unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined G9a's genome-architectural role and its oncogenic gain-of-function, showing it shapes chromatin accessibility/looping and drives WNT-dependent tumor growth and immune exclusion.\",\n      \"evidence\": \"ATAC-seq/ChIP-seq/Hi-C in depletion and catalytic-mutant ESCs; oncogenic mutation analysis with ChIP and in vivo melanoma models; recurrent tumor genetic ablation with necroptosis readouts\",\n      \"pmids\": [\"33113380\", \"32269030\", \"33147463\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting H3K9me2 loss to altered CTCF/cohesin binding unclear\", \"Catalytic vs scaffold contribution to looping not separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the biochemical basis of heterodimer superiority, defined SPOP-GLP-G9a stability control, and broadened oncogenic and substrate repertoire including GMFB methylation.\",\n      \"evidence\": \"Recombinant dimer reconstitution with nucleosomes and XL-MS; SPOP Co-IP/ubiquitination/methylome/xenografts; in vitro GMFB methylation with in vivo neuroprotection models; APC/ERVK ChIP in KO models\",\n      \"pmids\": [\"34619147\", \"34588438\", \"37307824\", \"34344448\", \"34519223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of full heterodimer absent\", \"In vivo mutagenesis validation for GMFB-K25 limited\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established scaffolding super-complexes (PALI1-PRC2, ZFP462, CHD4) coordinating dual H3K9/K27 methylation and immune evasion, and delivered first covalent G9a/GLP inhibitors with a crystallographic binding mode.\",\n      \"evidence\": \"Co-IP and ChIP-seq for PALI1 and ZFP462 complexes in cancer and ESC KO models; CRISPR screen and Co-IP for CHD4; covalent inhibitor synthesis with X-ray structure and cellular H3K9me2 assays\",\n      \"pmids\": [\"36476474\", \"36604593\", \"38065340\", \"35763668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants selecting dual-methylation target subsets unknown\", \"G9a vs GLP selectivity of covalent inhibitors only partial\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended oncogenic mechanisms to Notch activation via Fbxw7 silencing and c-Myc stabilization, reinforcing G9a as a transcriptional and protein-stability hub in cancer.\",\n      \"evidence\": \"ChIP/luciferase in glioma stem cells with immune profiling; c-Myc/G9a Co-IP and PDX models\",\n      \"pmids\": [\"36971192\", \"36896891\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether c-Myc stabilization is methylation-dependent unresolved\", \"Single-lab findings\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How G9a is targeted to specific genomic loci across its many partner-defined complexes, and what distinguishes its catalytic from scaffolding contributions at each target, remains the central unresolved question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of locus selection across Mediator/PRC2/CHD4/ZFP462 contexts\", \"Catalytic vs scaffold contribution not systematically dissected genome-wide\", \"Structural basis of heterodimer at nucleosomes incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 4, 16, 25, 34]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [16, 34]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [3, 25]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [7, 11, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [33]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [1, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 2, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 9, 15]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 27, 29, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 24, 31, 39]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [44, 21]}\n    ],\n    \"complexes\": [\n      \"G9a-GLP heterodimer\",\n      \"G9a-PALI1-PRC2 super-complex\",\n      \"G9a-DNMT1-PCNA ternary complex\",\n      \"G9a-Mediator complex\"\n    ],\n    \"partners\": [\n      \"GLP\",\n      \"DNMT1\",\n      \"PCNA\",\n      \"EZH2\",\n      \"RPA\",\n      \"MEF2C\",\n      \"CHD4\",\n      \"ZFP462\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":7,"faith_total":7,"faith_pct":100.0}}